Printer Friendly

EMBREX REPORTS THIRD QUARTER AND NINE MONTH RESULTS

 EMBREX REPORTS THIRD QUARTER AND NINE MONTH RESULTS
 RESEARCH TRIANGLE PARK, N.C., Dec. 20 /PRNewswire/ -- Embrex Inc.


(NASDAQ: EMBX, EMBXW) today reported financial results for the third quarter and nine months ended Sept. 30, 1991.
 The results were reported in conjunction with the required filing of a form 10-Q with the Securities and Exchange Commission within 45 days of becoming a public company, which occurred on November 7.
 Embrex reported a net loss of $1,133,047 ($0.79 per share) for the third quarter of 1991 compared with a net loss of $924,083 ($0.82 per share) for the comparable period last year. No revenues were recorded in the 1991 quarter compared with total revenues of $28,664 during last year's quarter.
 For the first nine months of 1991, Embrex reported a net loss of $3,285,321 ($2.54 per share) and total revenues of $96,019 compared with a net loss of $2,662,710 ($2.37 per share) and total revenues of $28,664 for the 1990 period.
 The revenue increase for the nine month period came primarily from product sales and INOVOJECT(A) egg injection system revenues. INOVOJECT was launched in December 1990.
 The nine month period also reflected a write-down of the carrying value of first generation INOVOJECT systems held for lease and the carrying value of certain patents, which increased the net loss for the period by $352,455. A second generation INOVOJECT system is currently completing field trials at commercial hatcheries in North Carolina.
 No revenues were recorded in the third quarter as commercial operation of the first generation INOVOJECT system was suspended due to the presence in the customer's hatchery of a level of microorganisms deemed unsuitable for proper system operation.
 Embrex Inc. develops and has recently begun marketing bioscience and bioengineering-based products to increase the productivity and profitability of the poultry industry.
 (A) -- INOVOJECT is a registered trademark of Embrex Inc.
 EMBREX INC.
 (A Development Stage Company)
 Statements of Operations
 Periods ended Three months Nine months
 Sept. 30: 1991 1990 1991 1990
 Total revenues $ -- $ 28,664 $ 96,019 $ 28,664
 Total operating
 expenses 1,017,244 958,195 2,758,611 2,760,493
 Net loss (1,133,047) (924,083) (3,285,321) (2,662,710)
 Net loss per share
 of common stock ($0.79) ($0.82) ($2.54) ($2.37)
 Wtd. avg. shares of
 common stock
 outstanding 1,423,975 1,121,873 1,294,558 1,121,845
 -0- 12/20/91
 /NOTE TO EDITORS: INOVOJECT is a registered trademark of Embrex Inc./
 /CONTACT: John A. Hagan of Embrex, 919-941-5185; or Douglas Johnson of GreenTree Communications, 800-428-8796, for Embrex/
 (EMBX) CO: Embrex Inc. ST: North Carolina IN: MTC SU: ERN


TS -- NY006 -- 4196 12/20/91 07:36 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 20, 1991
Words:464
Previous Article:HYATT REGENCY MAUI GUESTS TO RECEIVE TOMORROW'S NEWS TODAY
Next Article:S&P ISSUES PREANNOUNCEMENTS
Topics:


Related Articles
EMBREX REPORTS FIRST-QUARTER RESULTS
Embrex Reports First-Time Annual Profit, Record Revenues For 1996
Correction To Embrex April 14 Release Company's Patent License Is Exclusive(Correction Notice)
Embrex, Tyson Agree On Long-Term Inovoject System Contract
Embrex Posts Third Quarter Gains On Continued Growth.
Embrex Selects iAdvantage Software to Power Research and Development Data Management; Embrex to use the iAdvantage Biotech Management System for...
Embrex Reports Third Quarter 2003 Financial Results.
Embrex Reports Third Quarter 2004 Financial Results.
Embrex Reports Third Quarter 2005 Financial Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters